Institut Català de la Salut
[Casado JA, Valeri A, Sanchez-Domínguez R, Vela P, López A, Navarro S] Division of Innovative Therapies, CIEMAT and Advanced Therapies Unit, IIS-Fundación Jimenez Diaz and Autónoma University, Madrid, Spain. Biomedical Center for Research on Rare Diseases (CIBERER), Madrid, Spain. [Díaz de Heredia C] Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-09-09T12:50:57Z
2022-09-09T12:50:57Z
2022-08-01
Cellular immune response; Immunology; Stem cells
Respuesta inmune celular; Inmunología; Células madre
Resposta immune cel·lular; Immunologia; Cèl·lules mare
Fanconi anemia (FA) is the most prevalent inherited bone marrow failure (BMF) syndrome. Nevertheless, the pathophysiological mechanisms of BMF in FA have not been fully elucidated. Since FA cells are defective in DNA repair, we hypothesized that FA hematopoietic stem and progenitor cells (HSPCs) might express DNA damage–associated stress molecules such as natural killer group 2 member D ligands (NKG2D-Ls). These ligands could then interact with the activating NKG2D receptor expressed in cytotoxic NK or CD8+ T cells, which may result in progressive HSPC depletion. Our results indeed demonstrated upregulated levels of NKG2D-Ls in cultured FA fibroblasts and T cells, and these levels were further exacerbated by mitomycin C or formaldehyde. Notably, a high proportion of BM CD34+ HSPCs from patients with FA also expressed increased levels of NKG2D-Ls, which correlated inversely with the percentage of CD34+ cells in BM. Remarkably, the reduced clonogenic potential characteristic of FA HSPCs was improved by blocking NKG2D–NKG2D-L interactions. Moreover, the in vivo blockage of these interactions in a BMF FA mouse model ameliorated the anemia in these animals. Our study demonstrates the involvement of NKG2D–NKG2D-L interactions in FA HSPC functionality, suggesting an unexpected role of the immune system in the progressive BMF that is characteristic of FA.
This work was supported by the “Ministerio de Ciencia e Innovación y Competitividad y Fondo Europeo de Desarrollo Regional (FEDER)” (SAF2015-68073-R, SAF2015-64152-R, and RTI2018-097125-B-I00); Next Generation EU; Plan de Recuperación Transformación y Resilencia (Instituto de Salud Carlos III; TERAV) (RD12/0019/0023); Programs of the European Commission (HEALTHF5-2012-305421 and EUROFANCOLEN); the “Ministerio de Sanidad, Servicios Sociales e Igualdad” (EC11/060 and EC11/550 “Comunidad de Madrid” (AvanCell, B2017/BMD-3692); and the ICREA-Academia program.
Article
Published version
English
Anèmia de Fanconi; Cèl·lules mare hematopoètiques; Regulació genètica; DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia::Anemia, Aplastic::Anemia, Hypoplastic, Congenital::Fanconi Anemia; ANATOMY::Cells::Bone Marrow Cells::Hematopoietic Stem Cells; PHENOMENA AND PROCESSES::Genetic Phenomena::Gene Expression Regulation::Up-Regulation; ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::anemia::anemia aplásica::anemia hipoplásica congénita::anemia de Fanconi; ANATOMÍA::células::células de la médula ósea::células madre hematopoyéticas; FENÓMENOS Y PROCESOS::fenómenos genéticos::regulación de la expresión génica::regulación positiva
American Society for Clinical Investigation
The Journal of Clinical Investigation;132(15)
http://dx.doi.org/10.1172/JCI142842
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]